icon-folder.gif   Conference Reports for NATAP  
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
6-Week Treatment With Ledipasvir (NS5A Inhibitor) Plus GS-9451 (NS3 Inhibitor) With Peg-IFN/RBV in Naïve IL28B CC Subjects With Genotype 1 CHC: High Rates of Sustained Virological Response
  Reported by Jules Levin
EASL 2013 April 26 Amsterdam
Alexander Thompson1, Steve Han2, Mitchell Shiffman3, Lorenzo Rossaro4, Reem Ghalib5, Kimberly L. Beavers6, Stephen Pianko7, Xiaoru Wu8, James Trenkle8, Bittoo Kanwar8, Mani Subramanian8, John McHutchison8, Andrew J. Muir9, Sam Lee10, Jacob George11 1St. Vincent's Hospital Melbourne, Australia; 2University of California, Los Angeles, CA, USA; 3Liver Institute of Virginia, Norfolk, VA, USA; 4University of California, Davis, Sacramento, CA, USA; 5The Liver Institute at Methodist Dallas Medical Center, Dallas, TX, USA; 6Asheville Gastroenterology Associates, Asheville, PA, USA; 7Monash Medical Center, Clayton, Australia; 8Gilead Sciences, Foster City, CA, USA; 9Duke Clinical Research Institute, Durham, NC, USA; 10University of Calgary, Calgary, Canada; 11Westmead Hospital, Westmead NSW, Australia
Apparently development of Gilead protease GS9451 has been stopped. 2 cases of pancytopenia out of 500 patients, one in each of 2 quad studies that included GS9451 were seen.